Degree Type

Creative Component

Semester of Graduation

Fall 2020

Department

Family and Consumer Sciences

First Major Professor

Dr. Ruth MacDonald

Degree(s)

Master of Family and Consumer Sciences (MFCS)

Major(s)

Family and Consumer Sciences

Abstract

The high incidence of obesity contributes to increased risk for chronic diseases and is an economic burden. In those with a BMI of ≥ 40 kg/m2 (severe obesity), or ≥ 35 kg/m2 with obesity related chronic diseases, bariatric surgery is the only available treatment that results in significant and sustained weight loss. However, bariatric surgery is expensive and has associated risks. An emerging treatment is the use of intragastric balloon which is becoming popular in America, as it’s non-surgical, helps with early satiety and is temporary. It is often used in conjunction with a comprehensive lifestyle modification program. A study to determine the safety and efficacy of the Spatz3 device was conducted at the Center for Clinical and Translational Science, Mayo Clinic in Rochester, Minnesota during 2017-2019. The purpose of this study was to evaluate the safety and effectiveness of the Spatz3 balloon in subjects with BMI between 30 and 40 who had failed to achieve and maintain weight loss with a weight control program. Eligible 288 Subjects were studied in a randomized, controlled, multi-center study. The control group received individualized diet and exercise counseling for 32 weeks. The treatment group received individualized diet and exercise counseling plus the Spatz3 balloon for 32 weeks followed by counseling alone for 23 weeks. This paper offers the RD an insight into the rationale for the emerging non-surgical obesity treatment, history of intra-gastric balloons, evidence of their efficacy, experiences of conducting a study and guidelines for appropriate nutritional care of patients post implantation.

Copyright Owner

Nayar, Sunita

File Format

Word

Embargo Period (admin only)

7-13-2020

1

Share

COinS